



EXPEDITION 3 Study


www.Expedition3Study.com

Information for potential participants

An option worth considering

We understand that having issues with your memory and/or thought processes can be worrying. And it's perfectly natural to want to think carefully about what to do next and discuss your

options with your family. When you do, consider EXPEDITION 3 - a clinical research study looking at an investigational drug for mild Alzheimer's disease (AD).



This booklet will tell you a little about EXPEDITION 3 and what to do if you think you'd like to take part.

What is a clinical research study?

Clinical research studies are scientific investigations that help us find better treatments. For example, some studies look for completely new medicines while others see whether an existing medicine could be used for another purpose.

Before a new medication is approved to be sold as a treatment for an illness it must be proven to be safe and effective in research studies which investigate how people react to the medication in a carefully controlled setting. Every year, thousands of people

choose to take part in clinical research studies to gain access to new medications and to help scientists understand more about illnesses and how treatments for them may work.



There can sometimes be risks to participating in clinical research studies, but participants are very carefully monitored for any signs that they may not be reacting to a medication as expected.

What is EXPEDITION 3 looking at?

Coping with memory and/or thought processing problems can be upsetting and frustrating. That's why EXPEDITION 3 will look at whether this investigational drug may help slow the worsening of AD in patients with mild disease.



About 2,100 people will take part around the world – people who (among other things):

- *Are 55-90 years old*
- *Have mild AD (you will have tests at Visit 1 to see if you are eligible for the study)*
- *If you are considering taking part, you should also have a friend, relative or loved one who spends at least 10 hours a week with you and can:*
 - *Attend your clinic visits with you*
 - *Be available to answer questions about you*

If you'd like to join the EXPEDITION 3 study, the study team will assess your health and condition fully during a clinic visit to make sure you're able to take part. And if you're not, don't worry – your doctor will help you consider other options.

What treatment would I get?

During EXPEDITION 3, half the participants will receive the investigational drug and the other half will receive a placebo. A computer will randomly choose which of the two treatments you receive. This means that you, your chosen study partner, your doctor and the study team will not know which treatment group you were assigned to.

What is a placebo?


Placebos don't contain any medicine. They look exactly like the drug they're being compared to and participants receiving them receive the same care and monitoring as those receiving the investigational drug. This helps ensure that any changes we see are due to the investigational drug only. Also, if a person

thinks they're taking a medicine, sometimes their health improves even if they're actually taking a placebo! This mysterious and unexplained phenomenon is known as the placebo effect.



How are the treatments given?

Both the investigational drug and the placebo will be given as an intravenous infusion (sometimes called an 'IV' or 'drip') by a study team member at every visit (except Visits 1 and 22). The infusion will take around 30 minutes to administer – many people bring a magazine or book to read to pass this time.



How long will EXPEDITION 3 last?

Your participation in EXPEDITION 3 would last for approximately 18 months. However, if you complete the study, you may be able to enter an open label extension study where all participants receive active investigational drug. As with any study, participation in the extension study is voluntary.



What will happen during the study visits?

Over the study's 18 months, you'll attend at least 22 clinic visits (some of which may take more than a day) to monitor your health and condition using assessments such as:



ECGs (a painless look at your heart)



MRI scan (a painless way to take a picture of your brain)



Questionnaires about your memory and/or thought processes



Urine and blood tests

At the beginning and end of the study, you will be asked to have either a PET scan (another type of painless brain scan using radioactive dye) or a lumbar puncture, depending on which procedure is available at the study site. During the lumbar puncture, a small amount of spinal fluid is removed using a needle at your lower spine to test for certain things. Please be reassured that either test is a standard procedure carried out on thousands of patients every year. Whichever procedure you had in the beginning will be repeated at the end of your participation in the study.

It's important to note that attending every visit is vital – the study team should be contacted to reschedule any missed appointments.

Is there anything else that I should know?

Before you join EXPEDITION 3, both you and your study partner would need to sign an informed consent form (ICF). This would show that you both understand and agree to what the study involves. However, as your participation is voluntary, you could withdraw this consent at any time (even after signing the

form) without affecting your usual healthcare.

And finally, even though taking part can't guarantee that your health will improve, you can still help to further the understanding of AD and help develop future treatments.

Thank you for your time and interest

Please contact the study team if you have any questions or you'd like to learn more.



EXPEDITION 3 Study

www.Expedition3Study.com

Study team contact details:

Karen Kearns, Research
Coordinator/Practice Manager

Phone: (805)278-4148